Streetbeat News

Versus Systems Inc.

https://www.versussystems.com

Industry

Software - Application

Versus Systems Inc. develops and operates a business-to-business software platform in the United States and Canada. The company operates eXtreme Engagement Online, a platform that allows live event producers, professional sports franchises, video game publishers and developers, live event producers, and professional sports franchises, as well as other interactive media content creators, to offer in-game prizing and rewards based on the completion of in-content challenges alongside other user engagement tools. It primarily sells its access to platform and service offerings through its direct sales organization. Versus Systems Inc. is headquartered in Vancouver, Canada.

Open

1.68

Mkt cap

4.5M

Volume

38K

High

1.69

P/E Ratio

-0.35

52-wk high

9.59

Low

1.61

Div yield

N/A

52-wk low

1.00

HC Wainwright & Co. has maintained a Neutral rating on Versus Systems (NASDAQ:VS) while raising the price target from $1.5 to $3. This suggests a potential upside in the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 10:43 am

TSMC shares surged 8.1% in pre-market trading due to better-than-expected Q3 results, with revenue up 39% YoY. Other stocks like Staffing 360 Solutions and Gevo also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 17, 2024 | 9:39 am

U.S. stocks rose with the Dow Jones gaining over 300 points. Morgan Stanley reported strong Q3 results, beating estimates with a 33% increase in net earnings. 180 Life Sciences, Altus Power, and Versus Systems saw significant stock price increases, while Service Properties Trust, Silvaco Group, and Novavax experienced declines.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 6:53 pm

U.S. stocks rose with the Dow Jones gaining over 250 points. U.S. Bancorp reported better-than-expected earnings, while other companies like 180 Life Sciences and Altus Power saw significant stock movements. Novavax faced a setback with an FDA clinical hold.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 4:26 pm

US stocks showed mixed performance with the Dow Jones slightly up, while NASDAQ and S&P 500 fell. Abbott Laboratories reported better-than-expected Q3 results, boosting its stock. Several other stocks experienced significant price movements due to various announcements and results.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 2:03 pm

Versus Systems shares have resumed trading after a temporary halt. This development is significant for investors as it may impact the stock's short-term price movement.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 2:02 pm

Versus Systems shares surged 489% following a $2.5 million investment and licensing deal with ASPIS. Novavax shares dropped 32% after the FDA placed a clinical hold on its vaccine candidates. Biodexa Pharmaceuticals shares rose 245% after successfully appealing Nasdaq's delisting decision.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:23 pm

Versus Systems Inc. (NASDAQ:VS) shares surged over 300% premarket due to two major agreements with Aspis Cyber Technologies. These include a $2.5 million investment and a licensing deal for Versus' technology. The agreements aim to help Versus meet Nasdaq's equity requirements.

Portfolio Pulse from Lekha Gupta

October 16, 2024 | 11:56 am

Versus Systems shares rose following a $2.5 million investment and licensing agreement with ASPIS.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:53 am

Versus Systems has announced a $2.5 million investment and licensing agreement with ASPIS to meet Nasdaq's compliance requirements. This move is part of their plan to maintain the minimum shareholders' equity needed for continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 7:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.